Zomedica Corp. · OTC:ZOMDF
Zomedica — H.C. Wainwright Global Investment Conference 2022
28 slides from Zomedica's conference presentation, May 31, 2022
Slide 1: “It’s All In The Waves”
WN <> ZOMEDICA “It’s All In The Waves” Larry Heaton Chief Executive Officer ZOM LISTED NYSE AMERICAN 5/31/2022
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Zomedica Investment Highlights
Zomedica Investment Highlights Zomedica’s new sales and marketing team is Strong balance sheet for commercializing two unique continued Business platforms with compelling Development activity razor/ razor blade economics Animal health market is growing at Highly experienced and 9% CAGR, and is expec
Slide 4: Experienced Management Team with Decades of Expertise
EXPERIENCED MANAGEMENT TEAM WITH DECADES OF EXPERTISE Larry Heaton Ann Cotter Tony Blair Adrian Lock Greg Blair Nicole Westfall Evan St. Peter Chief Executive Executive VP, VP, General Manager VP, Bus Dev & VP, Technology Chief Financial Officer VP, Marketing Officer Operations Head of Sales Strateg
Slide 5: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Clinically Proven Global TRUFORMA® Leader Reference Lab Quality with Drive assay utilization Point of Care Convenience Expand installed Launch into Expand Equine Indications Expand assay offerings base of clinical sites small animal for use to grow utilization
Slide 6: Companion Animal Diagnostics – Large and Growing Addressable Market
Companion Animal Diagnostics – Large and Growing Addressable Market Proof… Veterinarians cite Diagnostics are diagnostics testing increasingly important to practice health as Vet volume growth as a Pharma shifts to online top driver of practice and retail channels.(2) economics (3) 10% JP Morgan est
Slide 7: TRUFORMA Seeks to Change this Dynamic for Veterinarians, Patients and Pet Parents
Zomedica believes that existing in-clinic testing platforms do not provide the accuracy and precision necessary for the timely diagnosis and treatment of certain conditions TRUFORMA® Seeks to Change this Dynamic for Veterinarians, Patients and Pet Parents 7
Slide 8: Based on clinically proven Bulk Acoustic Wave (BAW) technology
• Based on clinically proven, highly sensitive Bulk Acoustic Wave (BAW) technology • Developed and commercialized by Qorvo in Telecom & Aerospace industries • FDA emergency use authorization for COVID testing by Qorvo Biotechnologies Disposable Compact Timely and Cartridge Instrument Accurate Preloa
Slide 9: TRUFORMA Assay Development Targets
TRUFORMA® Assay Development Targets Multiple assay targets drive utility for the practitioner. On the Market In Development Potential Opportunities Adrenal & Thyroid Panel for Dogs Expanding into high value Point Becoming a broad-based Point and Cats of Care solutions of Care lab solution Now Availa
Slide 10: Commercialization Imperatives
Commercialization Imperatives • Grow Installed Base • Customer Appreciation Program facilitates growth in installed base by “placing” instruments with no capital required • Drive Utilization • MyZomedica portal provides easy-to-read test results and easy-to-use ordering process • Providing clinical
Slide 11: Focus on Sales & Marketing
Focus on Sales & Marketing Multiple Sales Channels Building sales teams with multiple paths to sell - remotely, in-person and with the assistance of Veterinarians employed by Zomedica Expanding Sales Team Inside Sales, Field Sales, Professional Service Vets, PulseVet Reps Newly Established Marketing
Slide 12: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Clinically Proven Global TRUFORMA® Leader Reference Lab Quality with Drive assay utilization Point of Care Convenience Expand installed Launch into Expand Equine Indications Expand assay offerings base of clinical sites small animal for use to grow utilization
Slide 13: PulseVet Shock Wave Therapy Available for Equine and Small Animal
PulseVet Shock Wave Therapy Available for Equine and Small Animal
Slide 14: Wonder if PulseVet treatments really work? See for yourself!
Wonder if PulseVet treatments really work? BEFORE See for yourself ! P U L S E V E T T R E AT M E N T QUICK CLINIC VISIT AFTER P U L S E V E T T R E AT M E N T
Slide 15: PulseVet Overview
PulseVet® Overview Zomedica acquired Pulse Veterinary Technologies LLC on October 1, 2021 • PulseVet shock wave therapy is the global market leader and enjoys wide adoption in equine uses for over 40 clinical applications • Over 1,500 systems actively in use; 75% in North America and 25% in the ROW,
Slide 16: Equine Growth Drivers
Equine Growth Drivers New • First-time purchases by equine Veterinarians continue to grow. Placements • Additional units for busy practices, second locations, multiple Veterinarians. • Upgrades of discontinued models and devices greater than 5 years old System Upgrades • Current ProPulse model is li
Slide 17: Small Animal Opportunity
Small Animal Opportunity Units Sold Experiencing Rapid Growth 35 Passionate Early 30 Levarage Sales Total Adopters Footprint Addressable 25 Existing commercial team Market Multiple clinical studies for canine use generated remains in place US companion animal market 20by Early Adopters experiencing
Slide 18: PulseVet Market Opportunity
PulseVet® Market Small Animal = 30,000 US accounts Opportunity 25% penetration of Small Animal market: - 7,500 Practices; $225 million in Capital Revenue - $50 million in Annual Consumable Revenue Equine Penetration ~25% of 25% of Small Animal Greenfield 4450 accounts Current Run Rate: $16 million/y
Slide 19: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Clinically Proven Global TRUFORMA® Leader Reference Lab Quality with Drive assay utilization Point of Care Convenience Expand installed Launch into Expand Equine Indications Expand assay offerings base of clinical sites small animal for use to grow utilization
Slide 20: VetGuardian Remote Pet Monitoring
VetGuardian™ Remote Pet Monitoring • VetGuardian is the only completely wireless platform to continuously monitor vital signs in pets. • Post-surgical and overnight monitoring is critical to good outcomes in pets. • VetGuardian provides peace of mind by alerting the clinic staff if vital signs devia
Slide 21: Investment in VetGuardian
Zomedica Investment in VetGuardian • Zomedica recently invested $1m in a convertible note in Structured Monitoring Products, the makers of VetGuardian to collaborate on bringing this critical clinical tool to market. • Zomedica and SMP will collaborate on final design and manufacturing scaling proce
Slide 22: Sniffing out Future Technologies
Sniffing out Future Technologies
Slide 23: Business Development Opportunities
Business Development Opportunities Strong Adding to Accelerating Balance Sheet Product Portfolio Innovation • $192 million net cash • PulseVet is first step in • Industry innovation position as of 3/31/2022 expected build-out accelerating • VetGuardian investment • ZOM in active discussions accelera
Slide 24: Financial Foundation & Performance
Financial Foundation & Performance 2022 Balance Sheet as of 3/31/2022 First Quarter 2022 Profit & Loss Statement ($($000's) 000's) ($ 000's) 1Q2022 Cash and Cash Equivalents $ 192,337 Net Revenue $ 3,751 Cost of Revenue 990 Other Current Assets 6,113 Gross Profit 2,761 Total Current assets: 198,450
Slide 25: Substantial Year-Over-Year Revenue Growth
Substantial Year-Over-Year Revenue Growth Diagnostics net revenue (United Stated dollars in thousands) Therapeutics net revenue (United Stated dollars in thousands) $70 $4,000 $3,694 +36% $60 +307% $57 $3,000 $2,700 $50 $40 $2,000 $30 $20 $1,000 $10 $14 $900 $0 $0 $150 Q1-2021 Q1-2022 Q1-2021 Q1-202
Slide 26: Why Invest In Zomedica?
Why Invest In Zomedica? TRUFORMA® provides revolutionary Increasing revenues and attractive PulseVet® continues to grow equine reference lab accuracy with point of care gross margins provide pathway to business both in the US and internationally convenience. Continued investment in assay profitabili
Slide 27: “It’s All In The Waves”
— Investor Relations Contact: —Kirin Smith, President PCG Advisory Inc 646-823-8656 | ksmith@pcgadvisory.com 5/31/2022 <> ZOMEDICA “It’s All In The Waves” ZOM SKSHAEID) NYSE AMERICAN 27
Slide 28: Appendix - Endnotes
Appendix - Endnotes (1) JP Morgan coverage initiation report on Idexx and Heska, January 2021 (2) JP Morgan AH Industry overview Jan 2021 (3) Credit Suisse Animal Health Industry Primer, June 2021 Pg 16 Grandview Research August 2021 Global Market Insights 2016 pet owner survey conducted by The Huma
Zomedica — H.C. Wainwright Global Investment Conference 2022 on 6ix